SCHEMBL19285288

SCHEMBL19285288

COC(OC)C1(COc2ccc(C(=O)OC(C)(C)C)cc2[N+](=O)[O-])CCOc2cc(Cl)ccc21

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.37
▸ KMT2A Q03164 5/20 0.37
▸ MEN1 O00255 4/20 0.37
▸ MAP3K14 Q99558 1/20 0.36
▸ ALDH1A1 P00352 8/20 0.35
▸ RAB9A P51151 3/20 0.35
▸ POLB P06746 2/20 0.35
▸ LMNA P02545 3/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ HPGD P15428 3/20 0.34
▸ NPSR1 Q6W5P4 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ TDP1 Q9NUW8 2/20 0.34
▸ NPC1 O15118 2/20 0.33
▸ GAA P10253 1/20 0.33
▸ HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29553896 1.00 MAPT (0.37) MAPTKMT2AMEN1MAP3K14ALDH1A1
SCHEMBL19285289 1.00 MAPT (0.37) MAPTKMT2AMEN1MAP3K14ALDH1A1
SCHEMBL23670425 0.90 MAPT (0.40) MAPTKMT2AMEN1MAP3K14ALDH1A1
SCHEMBL17542342 0.85 KDM4E (0.36) MAPTKMT2AMEN1ALDH1A1RAB9A
SCHEMBL19284802 0.85 ALDH1A1 (0.36) MAPTKMT2AMEN1ALDH1A1RAB9A
SCHEMBL29554048 0.85 ALDH1A1 (0.36) MAPTKMT2AMEN1ALDH1A1RAB9A
SCHEMBL17542198 0.85 KDM4E (0.36) MAPTKMT2AMEN1ALDH1A1RAB9A
SCHEMBL29436682 0.85 KDM4E (0.36) MAPTKMT2AMEN1ALDH1A1RAB9A
SCHEMBL19284747 0.85 MAPT (0.39) MAPTKMT2AMEN1MAP3K14ALDH1A1
SCHEMBL22894770 0.85 MAPT (0.39) MAPTKMT2AMEN1MAP3K14ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12091425-B2 Compounds that inhibit MCL-1 protein AMGEN INC. (US) 2024-09-17 — — US disclosed
US-20230052348-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN AMGEN INC. (US) 2023-02-16 — — US disclosed
US-11306107-B2 Compounds that inhibit MCL-1 protein AMGEN INC. (US) 2022-04-19 — — US disclosed
US-20210230189-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN AMGEN INC. (US) 2021-07-29 — — US disclosed
WO-2017147410-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN AMGEN INC. (US) 2017-08-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210230189-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN MCL1, BCL9, BCL2L1 MAPT 3153/4885KMT2A 1766/4885MEN1 999/4885
US-11306107-B2 Compounds that inhibit MCL-1 protein MCL1, BCL9, BCL2L1 MAPT 3153/4885KMT2A 1766/4885MEN1 999/4885
US-20230052348-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN MCL1, BCL9, BCL2L1 MAPT 3153/4885KMT2A 1766/4885MEN1 999/4885
US-12091425-B2 Compounds that inhibit MCL-1 protein MCL1, BCL9, BCL2L1 MAPT 3153/4885KMT2A 1766/4885MEN1 999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback